Yearly Archives: 2025

Following discussions between Community Pharmacy England and the Department of Health and Social Care (DHSC) regarding medicine pricing issues reported by pharmacy owners, the Department has today (18/03/2025) announced the following initial list of price concessions for March 2025: Drug  Pack size Price concession Alfuzosin 2.5mg tablets 60 £4.46 Bimatoprost 300micrograms/ml / Timolol 5mg/ml eye [...]

The post March 2025 Price Concessions 1st Update appeared first on Community Pharmacy England.

Following discussions between Community Pharmacy England and the Department of Health and Social Care (DHSC) regarding medicine pricing issues reported by pharmacy owners, the Department has today (18/03/2025) announced the following initial list of price concessions for March 2025: Drug  Pack size Price concession Alfuzosin 2.5mg tablets 60 £4.46 Bimatoprost 300micrograms/ml / Timolol 5mg/ml eye [...]

The post March 2025 Price Concessions 1st Update appeared first on Community Pharmacy England.

Janet Morrison, Chief Executive of Community Pharmacy England, said: “With April rapidly approaching there have been a number of queries about the timings of the CPCF negotiations. As well as additional funding, pharmacy owners desperately need clarity about the future; many are already making impossible decisions to help their businesses to survive and to protect [...]

The post CPCF Negotiations appeared first on Community Pharmacy England.

Community Pharmacy England has released a summary of the March 2025 meeting of the Community Pharmacy IT Group (CP ITG).  The group are due to several key topics, including: Pharmacy IT development Electronic Prescription Service (EPS) extended to Detained Estate EPS clinical prescription tracker and EPS FHIR update Leveraging IT solutions to enhance patient engagement [...]

The post Pharmacy IT workstreams update published after IT group meets appeared first on Community Pharmacy England.

National Patient Safety Alert: Discontinuation of Promixin® (colistimethate) 1-million unit powder for nebuliser solution unit dose vials National Patient Safety Alert Reference Number: NatPSA/2025/001/DHSC Date issued: 17 March 2025 Explanation of identified safety issue Promixin® (colistimethate) 1-million-unit powder for nebuliser solution unit dose vials (UDVs) are being discontinued from early May 2025, with stocks anticipated [...]

The post National Patient Safety Alert: Discontinuation of Promixin® (colistimethate) 1-million unit powder for nebuliser solution unit dose vials appeared first on Community Pharmacy England.